The aim of this study was to investigate the effects of resveratrol against fumonisin B 1 (FB 1 )-induced liver toxicity, as, to the best of our knowledge, these effects have not been investigated yet, even though the toxic effects and mechanisms of FB 1 and the antioxidative effects of resveratrol are well known. 40 BALB/c mice were divided into control, FB 1 , resveratrol, and FB 1 +resveratrol groups. Control received saline for 14 days. The FB 1 group received 2.25 mg/kg FB 1 every other day for 14 days. The resveratrol group received 10 mg/kg resveratrol for 14 days. The FB 1 +resveratrol group received 2.25 mg/kg FB 1 every other day and 10 mg/kg resveratrol every day for 14 days. All administrations were peritoneal. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total sialic acid (TSA) levels were analysed in serum samples, while total antioxidant status (TAS) and total oxidant status (TOS) were measured in the liver. Additionally, the liver tissue was examined for histopathological changes. AST, ALT, and TSA were significantly higher in the FB 1 group than control. Resveratrol countered FB 1 effects for all parameters, including TOS and TAS. Liver histology showed FB 1 -induced hyperaemia, infiltrations, and megalokaryosis in some hepatocytes. No pathological findings were detected in the control, resveratrol, or FB 1 +resveratrol group. Our findings confirm resveratrol's protective effect against liver damage and oxidative stress caused by FB 1 . In addition, they suggest that increased serum TSA levels can be used as a biomarker of FB 1 -induced hepatotoxicity.